UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2684-2690

2012

Volltextzugriff (PDF)

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

Clinical cancer research, 2010-02, Vol.16 (4), p.1289-1297

2010

Volltextzugriff (PDF)

Prevalence of hypercalcemia among cancer patients in the United States

Cancer medicine (Malden, MA), 2016-08, Vol.5 (8), p.2091-2100

2016

Volltextzugriff (PDF)

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

The New England journal of medicine, 2020-04, Vol.382 (14), p.1331-1342

2020

Volltextzugriff (PDF)

Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

Biomedicines, 2015-03, Vol.3 (1), p.149-181

2015

Volltextzugriff (PDF)

GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

Clinical cancer research, 2011-11, Vol.17 (22), p.7174-7182

2011

Volltextzugriff (PDF)

Denosumab for Treatment of Hypercalcemia of Malignancy

The journal of clinical endocrinology and metabolism, 2014-09, Vol.99 (9), p.3144-3152

2014

Volltextzugriff (PDF)

Local Complexity of Amino Acid Interactions in a Protein Core

Proceedings of the National Academy of Sciences - PNAS, 2004-01, Vol.101 (1), p.111-116

2004

Volltextzugriff (PDF)

Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment

JNCI : Journal of the National Cancer Institute, 2013-09, Vol.105 (18), p.1417-1420

2013

Volltextzugriff (PDF)

Food and oral antineoplastics: more than meets the eye

Clinical cancer research, 2010-09, Vol.16 (17), p.4305-4307

2010

Volltextzugriff (PDF)

Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies

Cell cycle (Georgetown, Tex.), 2015, Vol.14 (21), p.3434-3440

2015

Volltextzugriff (PDF)

RE: Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials

JNCI : Journal of the National Cancer Institute, 2013-06, Vol.105 (11), p.833-833

2013

Volltextzugriff (PDF)

Reply to A. Levy et al

Journal of clinical oncology, 2013-01, Vol.31 (3), p.396-396

2013

Volltextzugriff (PDF)

A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors

Investigational new drugs, 2011-12, Vol.29 (6), p.1420-1425

2011

Volltextzugriff (PDF)

Response

JNCI : Journal of the National Cancer Institute, 2014-07, Vol.106 (7)

2014

Volltextzugriff (PDF)

A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3104-TPS3104

2018

Volltextzugriff (PDF)

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Blood, 2019-11, Vol.134 (Supplement_1), p.754-754

2019

Volltextzugriff (PDF)

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.TPS226-TPS226

2015

Volltextzugriff (PDF)

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7006-7006

2019

Volltextzugriff (PDF)

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.897-897

2018

Volltextzugriff (PDF)

ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS7075-TPS7075

2016

Volltextzugriff (PDF)

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3024-3024

2017

Volltextzugriff (PDF)

ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3102-TPS3102

2018

Volltextzugriff (PDF)

Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7006-7006

2018

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Oncology
(12)
Aged
(8)
Male
(8)
Middle Aged
(8)
Female
(7)
Adult
(6)
Treatment Outcome
(6)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Neoplasms - Drug Therapy
(5)
Neoplasms - Mortality
(5)
Neoplasms - Pathology
(5)
Tumors
(5)
Aged, 80 And Over
(4)
Antineoplastic Agents - Administration & Dosage
(4)
Dose-Response Relationship, Drug
(4)
Hypercalcemia - Etiology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Change in Tumor Size by RECIST Correlates Linearly With Overall Survival in Phase I Oncology Studies

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

Prevalence of hypercalcemia among cancer patients in the United States

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

Denosumab for Treatment of Hypercalcemia of Malignancy

Local Complexity of Amino Acid Interactions in a Protein Core

Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment

Food and oral antineoplastics: more than meets the eye

Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies

RE: Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials

Reply to A. Levy et al

A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors

Response

A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial

End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL)

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma

Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

Suchergebnisse filtern